Appearing in the Midas List of Top Tech Investors is no easy feat. Dr. Jim Tananbaum, Foresite Capital Founder and CEO has accomplished it not once but three consecutive times. A Forbes initiative, the list is created in an effort to recognize the top 100 leaders in the venture capital who provide uniquely great returns for their investors by going for the high stakes in the future tech companies.
A Strong Foundation
Dr. Tananbaum studied for his MBA at Harvard Business School, his MS at Massachusetts Institute of Technology, and his MD at Harvard Medical School. He also graduated from Yale University with a BS and B.S.E.E. In addition to his impressive educational background, he has more than 25 years of experience in the venture capital industry during which time he has been noted for success of Intarcia Therapeutics, Puma Biotechnology, Amira Pharmaceuticals, Jazz Pharmaceuticals, Healtheon, and Amerigroup deals.
Going for Top Talent
One of Dr. Jim Tananbaum’s latest additions to the San Francisco-based health care growth equity firm’s team is Dr. Molly He. Apart from earning a Nankai University biochemistry degree and a protein biophysics Ph.D. from the University of California, one of her greatest qualifications is having worked for more than 15 years in genomic as well as pharmaceutical research and development. According to Dr. Tananbaum, Dr. He has won respect and recognition in scientific research specifically in next generation sequencing. He applauded her not only for exemplary educational background and experience in development of genomics and drugs but also for her leadership talent. The former Illumina Senior Director joined Foresite Capital as venture partner and read full article.
Foresite Capital is headed for nothing less than the zenith under the leadership of Dr. Tananbaum. By getting Dr. He into the fold, he has succeeded in taking the firm more than a few steps towards its destiny. Jim of Twitter, Having been responsible for improvement and innovation for the Illumina’s protein reagent, she comes with a load of experience. Moreover, she has worked for Pacific Biosciences as the head of protein sciences where she was in charge of development of protein reagent. She has also published more than 20 papers in next-generation sequencing, what Jim knows.